The map held overnight — but pattern-hair-loss therapeutics are approaching a regulatory inflection

The four live themes were quiet overnight. Pattern hair-loss therapeutics sit at Frontier / Early Bridge: clinical and regulatory bridges strengthening, corporate capital confirmed (Veradermics), three public competitors mapped (Veradermics, Cosmo, Absci), but treated-population expansion remains unproven.

The established Momentum map was largely unchanged overnight. Four live themes — AI power, critical minerals, single-indication RAS oncology, and defense counter-autonomy — printed no new Level A evidence.

One frontier deserves increasing attention: **pattern hair loss** is moving closer to a regulatory and commercial inflection. The science is not new. What is changing is that multiple late-stage programs, substantial development capital, and a very large undertreated population are beginning to converge. The open question is not whether people lose hair — it is whether **the treated population can expand** as new drug classes reach the market with acceptable safety and reach patients through normalizing distribution channels.

Pattern hair-loss therapeutics — Frontier / Early Bridge

**Theme state:** Frontier / Early Bridge (Healthcare × Consumer crossover)
**Promotion state:** Not yet promoted to the core Momentum Map

**Pattern hair-loss therapeutics — Butterfly: Early Bridge**

| Bridge | Status |
|--------|--------|
| Clinical | Strengthening — multiple public late-stage programs |
| Regulatory | Strengthening — readouts and filings on defined clocks |
| Capital formation (corporate) | **Confirmed** — IPO and follow-on financing with disclosed runway |
| Consumer expansion (treated population) | **Unconfirmed** — the core Butterfly thesis |
| Institutional convergence (LongShort 13F) | Not yet tested |
| Crowding | Not yet established |

What we verified on primary chase

**Veradermics (NYSE: MANE)** — VDPHL01, oral extended-release minoxidil (non-hormonal). Positive Phase 2/3 male data. Confirmatory Phase 3 Study 304 expected **2H 2026**; female registration-directed Phase 2/3 fully enrolled, results **1H 2027**; registration-directed trials designed to support a planned NDA.

**Cosmo (SIX: COPN)** — clascoterone 5% topical androgen-receptor inhibitor (follicle-local; distinct from finasteride's systemic DHT suppression). Positive 12-month Phase III SCALP 1/2 data; NDA preparation underway; **U.S. filing planned early 2027**.

**Absci (NASDAQ: ABSI)** — ABS-201, injectable candidate (AI-designed biology; different mechanism from oral minoxidil or topical anti-androgen). Public competitor in the Wall Street "hair biotech" cluster; Eli Lilly invested $40M (2025). Interim clinical readouts were the next expected print — regulatory path behind Veradermics/Cosmo.

**Competitive map (three public names verified):** oral ER minoxidil (Veradermics) · topical AR blockade (Cosmo) · injectable novel biology (Absci). **Pelage / PP405** (follicle stem-cell metabolism; Phase 3 planned 2026) is a credible private program — not in the public three-name map.

The regulatory race supports a credible Early Bridge. Veradermics appears furthest along on filing timing; Cosmo on mechanism novelty at the follicle; Absci on differentiated delivery but earlier on the regulatory clock.

**Corporate capital is confirmed.** Veradermics IPO'd February 2026 and raised roughly **$472 million** in May; ~**$820 million** cash at June 30 (company disclosure). That is real financing — distinct from how we test **institutional ownership**:

- **Issuer-level (available now):** post-IPO trading, follow-on sizing, disclosed cash runway, strategic investments (e.g. Lilly into Absci).
- **Theme-level convergence (not yet tested):** LongShort 13F slice across the alopecia ecosystem — lagged; next full quarter slice pending in our ownership database.

Why not promoted to the core Momentum Map

Frontier / Early Bridge is an active research state — not the same as promotion into the four-theme core book. Promotion requires confidence that new treatments will **expand the treated population** — not merely shift share from finasteride and minoxidil.

**Next hunt priority (expansion, not efficacy):** DTC and telehealth adoption signals, search and prescribing behavior, patient willingness to treat, female-market expansion, dermatologist channel behavior, and launch conversion — not another isolated clinical headline.

What would invalidate

Phase 3 misses, safety profiles that block adoption, launches that only cannibalize generics without expanding treated prevalence, or female oral paths that fail to differentiate.

Established themes (unchanged overnight)

**AI / Technology — Strengthening.** SLB–Kelvion and nVent–Maverick **acquisitions/deals** stand (announced capital, not closed interconnection capacity); no new interconnection filing.

**Critical Minerals — Strengthening.** Public capital packages stand; Hemerdon offtake still unsigned.

**Healthcare / Biotech (RAS) — Emerging.** One labeled RAS(ON) use — confirmed, not a platform.

**Defense / Geopolitics — Strengthening.** May 19 cheap-intercept IDIQ is real; task-order quantities still unprinted.

**Gold — Consensus carry.**

**Corporate Distress —** No qualifying signal found in current coverage.

**Wildcards —** No qualifying signal found in current coverage.

What should happen next

**Frontier (expansion hunt):** prescription/DTC adoption proxies; search and prescribing trends; female-market uptake path; dermatologist behavior; launch conversion if a product reaches market — prove the treated population expands.

**Frontier (regulatory):** Veradermics Study 304 (2H 2026); Cosmo U.S. filing (early 2027); Absci interim clinical readout.

**Capital:** issuer-level filings and trading (ongoing); theme-level institutional convergence when the next complete 13F quarter is in our database.

**Maintain:** interconnection filing; signed Hemerdon offtake; cheap-intercept task orders; second RAS indication.